A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

Prior treatment

• Received non-steroidal anti-inflammatory drugs within 2 weeks before enrollment;
• Within 4 weeks before enrollment, he received traditional Chinese patent medicines and simple preparations or traditional Chinese medicine decoction, chemical drugs (such as sulfasalazine, methotrexate, leflunomide, hydroxychloroquine, cyclophosphamide, azathioprine, etc.), opioid analgesics (such as methadone, morphine, etc.), JAK inhibitor drugs (such as tofatib, etc.), and systemic glucocorticoid treatment;
• Received spinal or joint surgery treatment within 8 weeks prior to enrollment;
• Within 12 weeks prior to enrollment, biological agents with therapeutic effects on spinal arthritis have been used;
• Within 6 months prior to enrollment, corticosteroid injections were received into the joint cavity or spine/paravertebral area;
• Suspected or actual drug, substance, or alcohol abuse;
• Within 3 months prior to the trial or currently participating in clinical trials;

Other illness

• Subjects diagnosed with other rheumatic immune system diseases or immune deficiency syndrome, such as active ulcerative colitis, psoriasis, uveitis, etc;
• Serious heart, liver, kidney, brain, mental, and neurological disorders that affect informed consent and/or expression or observation of adverse events;

Lab values

• Abnormal liver function (elevated levels of alanine or alanine aminotransferase above the upper limit of normal values); Abnormal renal function (serum creatinine levels above the upper limit of normal values);

Other

• Those who meet any of the following criteria cannot be included in this experiment:
• CT indicates disappearance of sacroiliac joint space or complete spinal rigidity;
• Those who have fertility requirements within six months;
• Pregnant or lactating women;
• The researchers believe that it is not suitable to participate in this experiment.

• All of the following standards must be met:
• Age range from 18 to 65 years old (including 18 and 65 years old), regardless of gender;
• Meets the diagnostic criteria for axial osteoarthritis recommended by ASAS in 2009, and the condition is in an active phase. The criteria for determining disease activity are to meet two criteria: Bass ankylosing spondylitis disease activity index (BASDAI) ≥ 40mm (0-100mm, evaluated using VAS); Spinal pain score ≥ 40mm (0-100mm, evaluated using VAS);
• Conforming to the traditional Chinese medicine syndrome differentiation standards for kidney yang deficiency and blood stasis obstruction syndrome;
• CT examination of sacroiliac arthritis grades I (A) to II (B) (both included);
• Human leukocyte antigen B27 (HLA-B27) is positive;
• Elevated C-reactive protein (CRP)/hypersensitive C-reactive protein (hsCRP) and/or erythrocyte sedimentation rate (ESR);
• Voluntarily participate in this clinical trial and sign an informed consent form.